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was then possible to develop software for calculating the dose 
distribution at any angle made of the applicator with the surface. 
Results: The software calculates the dose distribution by varying the 
angle and the depth to which you want to know. The variation of 
homogeneity is very important. For an angle of 25°, the 
inhomogeneity in the surface plane is between 100 and 40 %. 
Conclusions: A software has been developed, based on the 
computation code PENELOPE to know the dose distribution at any 
depth as a function of angle applicator with the surface. 
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Purpose/Objective: IORT is becoming an increasingly popular 
approach for cancer treatment. Especially patients with very close or 
positive margins after resection or recurrent cancer benefit from 
IORT. For situations where a flat area (up to 6cm in diameter) has to 
be treated intraoperatively, new applicators for superficial treatment 
with a miniature x-ray source (INTRABEAM® System, Carl Zeiss Surgical 
GmbH, Oberkochen, Germany) were developed. They were evaluated 
using ionization chamber and film dosimetry. 
Materials and Methods: Each of the so called FLAT (1 – 6cm diameter) 
and SURFACE Applicators (1cm – 4cm diameter) consists of a radiation 
protective metal tube and a flattening filter, which converts the 
spherical dose distribution of the x-ray source into a flat one. The 
homogeneity of each dose distribution and depth dose measurements 
were evaluated using film dosimetry (Gafchromic EBT2 films, ISP, New 
Jersey, USA) in a solid water phantom (Gammex 457, Gammex Inc., 
Middleton, WI, USA) and a soft x-ray ionization chamber (Type 34013, 
PTW, Freiburg, Germany) in a water tank (Carl Zeiss Surgical GmbH, 
Oberkochen, Germany). 
Results: The FLAT Applicators show the best homogeneity, with a 
maximum standard deviation of 2.66%, in certain depths. In 1mm 
depth SURFACE Applicators show a lower field edge dose (compared to 
the central axis dose) of up to 31%, which corresponds to a 
geometrical error of 2mm. They also show a higher dose rate (0.53 -
1.78Gy/min in 5mm depth) and a steeper dose gradient compared to 
the FLAT Applicators (0.17 – 1.24Gy/min in 5mm depth). This results 
in a treatment time of 1.0 – 6.5min in an instance of a prescription of 
10Gy to the surface of the SURFACE Applicators, respectively 9.5 – 
61min in case of a prescription of 10Gy in 5mm depth from the surface 
of the FLAT Applicators. 
Conclusions: Generating flat dose distributions in a certain depth 
using the INTRABEAM® System and novel applicators result in an 
inhomogeneity at the surface of these applicators. To evaluate the 
exact extent of homogeneity there, further research based on Monte 
Carlo simulation is needed. But the results show that it is possible to 
perform a superficial localized IORT with shielding of the surrounding 
tissue and with minimum radiation protection requirements. 
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Purpose/Objective: A new method for in vivo dosimetry (IVD) during 
breast intraoperative radiation therapy (IORT) was carried out to 
improve informations on the dose actually delivered to the target and 
on the alignment of the shielding disk. With this method it is possible 
to acquire two bi-dimensional dose distributions: one just below the 
target and the other beyond the shielding disk.  
Materials and Methods: Breast IORT requires the protection of the 
tissues underneath the target volume. This is achieved by the surgeon 
positioning a shielding disk between the residual breast and the 
pectoralis fascia. The position of the disk is a very suitable location 
for performing IVD. In our experience we prepared two layers of 
radiochromic films, Gafchromic® EBT3 of the same size of the 
shielding disk, we fixed them by sterile tape to both sides of the disk, 
which was then delivered to the surgeon for subsequent placement. 
The gafchromic films were calibrated in dose for the two energy (6 
and 9 MeV) usually employed in breast cancer treatment to provide a 
bi-dimensional distribution in term of absolute dose. After each 
treatment the radiochromic films were read by a CCD scanner 
producing two digital images suitable for subsequent analysis. 
Results: The Department of Radiotherapy of Trieste has recently 
implemented a IORT dedicated electron-beam accelerator, the 
Intraop® Mobetron. The first patients were treated immediately after 
conservative surgery for breast carcinoma, and two in vivo dose maps 
were acquired for all of them. The image related to the film 
positioned on top of the disk allowed us to evaluate the mean 
absolute dose in a central area of the exposed field to compare with 
the prescribed dose. In all cases we obtained excellent agreement. 
The uniformity of the exposed area was also evaluated (Fig.1). 
  
 
Fig.1 – Images of the EBT3 Gafchromic® film located on the upper face 
of the shielding disk. a) Original image (green channel); b) 
Representation enhancing the dishomogeneities of the target. 
From the image related to the lower film position we were able to 
measure the dose that actually crosses the shielding. We employed 
new shielding disks provided by IntraOp® company, made by stacking a 
5 mm perspex layer, a 3 mm copper layer and 2 mm perspex layer. 
With these disks we always measured negligible transmission values. 
Geometrical analysis of the position of the exposed area can provide 
information about the extent of the unavoidable misalignment 
between the treatment field and the protective disk. In this way it is 
possible to evaluate the amount of dose that escapes from the 
shielding and that provides undesirable dose to healthy tissues. 
Conclusions: High dose IORT treatment requires high accuracy. For 
this reason IVD represents a very important test to evaluate the actual 
delivered dose. Gafchromic® EBT3 film prooves an effective and 
appropriate dosimeter to be surgically applied to the patient. The 
absolute dose measurement provides verification of the correct 
exposure to the target, as well as an estimation of the dose to the 
healthy tissue. 
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Purpose/Objective: To evaluate the local control and early late 
toxicity of IORT for localized prostate cancer. 
Materials and Methods: Between December 2009 and September 
2010, 8 patients with locally advanced prostate cancer or high 
local/systemic relapse risk were selected. We enrolled patients with ≤ 
70 years age, without clinical nodal disease, and at least two of 
following characteristics: pre-operative PSA >10 ng/ml and <20ng/ml; 
Gleason score ≥7; cT2c; or at least one of following characteristics: 
apical gland involved; pre-operative PSA >20ng/ml and <50ng/ml; 
Gleason score ≥8; cT≥3. Before the surgery the Ethical Board validated 
informed consent for adjuvant IORT was obtained. The surgery 
included radical prostatectomy with iliac-obturator lymphadenectomy 
and extemporaneous histological examination for nodal metastasis 
research. After prostate removal the patients were irradiated with 
IORT receiving a radical dose of 20 Gy in single fraction by 10 MeV 
electron beam. The IORT procedure was performed after bladder-
urethral anastomosis and confirmation of pathological negativity of 
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obturator nodes. In vivo dosimetry was performed by mosfet 
dosimeters inserted in rectal and Foley catheters. The toxicity was 
evaluated according to RTOG scale. 
Results: Of the 8 patients selected, 1 was excluded from IORT for 
nodal metastasis found during the extemporaneous histological 
examination and performed adjuvant external beam radiotherapy 
afterwards; 7 patients were treated with IORT 20 Gy after radical 
prostatectomy. One patient died several months after IORT for non-
cancer related causes. In 6/8 patients the pathological staging 
confirmed the clinical staging with the evidence of an high risk of 
relapse after surgery (see table). In 2 (pT2c pN0 Mo R0) patients 
prognostic factors for local relapse had overestimate the stage. No 
patients had acute toxicity. The average time of hospitalization was 6 
days (range 5-8). The median follow-up was 28 months (range 26-36). 
In 6/7 (86%) patients so far alive we didn't observe biochemical 
relapse (average PSA <0,008 ng/ml). No patient performed hormonal 
therapy. No early urinary or rectal toxicity ≥G1 was observed. 2/6 
(33%) patients reported late urinary stenosis easily resolved after 
dilatation. No patients had urinary incontinence.  
 
n.positive 
biopsies 
Positive 
apex 
Glaeason 
pre SR 
Gleason 
post SR 
Pathological 
stage 
Surgical  
margins (R) 
12+/12 si 3+4 3+4 pT3a pN0 M0 negative 
6+/13 si 4+5 4+5 pT3b pN0 M0 positive 
13+/16 si 4+3 3+4 pT2c pN0 Mo negative 
9+/17 si 4+3 4+3 pT3a pN0 M0 positive 
7+/12 si 4+3 4+5 pT2c pN0 Mo positive 
2+/18 si 4+4 4+4 pT3a pN0 M0 negative 
5+/14 si 3+4 4+3 pT2c pN0 Mo negative 
8+/13 si 4+4 4+4 pT3b pN1MO negative 
 
Conclusions: Our results, although on a small sample, reported after a 
median follow up of 28 months show excellent local control obtained 
with IORT on surgical bed with a very low toxicity. 
 
 
  
